Recurrent Melanoma Clinical Trial
Official title:
Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma
PRIMARY OBJECTIVES:
I. To determine the clinical response rate (Response Evaluation Criteria in Solid Tumors
[RECIST]) and one-year overall survival to the study drugs temsirolimus and AZD6244
(selumetinib) hydrogen sulfate in BRAF V600E mutant unresectable stage IV melanoma.
SECONDARY OBJECTIVES:
I. Estimate 6-month progression-free survival in patients receiving temsirolimus and AZD6244
hydrogen sulfate.
II. Determine the pharmacodynamic effects of temsirolimus and AZD6244 on pERK, s6K, PTEN and
mediators of apoptosis.
III. Determine the toxicity profile of temsirolimus with AZD6244 hydrogen sulfate.
OUTLINE:
Treatment Phase: This period begins with the first intravenous (through the vein) infusion
of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will
continue until Week 8 (Visit 4).
As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins
once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for
8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an
outpatient, unless admission to the hospital was needed for treatment of related side
effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be
given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.
The continuation phase begins with visits at weeks 12 in patients who receive at least two
cycles of treatments.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02224781 -
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
|
Phase 3 | |
Completed |
NCT01886235 -
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
|
N/A | |
Completed |
NCT00553306 -
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Completed |
NCT00019448 -
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT01748747 -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
|
Early Phase 1 | |
Terminated |
NCT01316692 -
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01120275 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00074308 -
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 | |
Completed |
NCT01989559 -
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
|
Phase 1 | |
Completed |
NCT00026143 -
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00006243 -
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
|
N/A | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Completed |
NCT01703507 -
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
|
Phase 1 | |
Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 |